POMDOCTOR LIMITED Successfully Completes Exercise of Underwriter's Over-Allotment Option

POMDOCTOR LIMITED's IPO Milestone

On October 10, 2025, POMDOCTOR LIMITED, a prominent online medical services provider focused on chronic diseases in China, announced the full exercise of the underwriter's over-allotment option related to its initial public offering (IPO). This move reflects the strong demand for the company's American Depositary Shares (ADSs), which trade on the Nasdaq under the ticker symbol `POM`.

The underwriter's option allowed for the purchase of an additional 750,000 ADSs at the public offering price of $4.00 each. As a result, POMDOCTOR has secured a total of $23,000,016 in gross proceeds from the offering, prior to deductions for underwriting discounts and related expenses.

The ADSs began trading on October 8, 2025, a significant step for POMDOCTOR in expanding its reach in the competitive healthcare market. Joseph Stone Capital, LLC acted as the underwriter for this successful offering.

Overview of POMDOCTOR LIMITED

POMDOCTOR LIMITED is recognized as a leader in China's internet hospital sector, specifically catering to chronic disease management. According to market research by Frost & Sullivan, the company ranked sixth in China's internet hospital market based on the number of contracted doctors in 2022. Their platform connects patients directly with healthcare providers, creating an integrated ecosystem that streamlines the delivery of medical services.

With a focus on efficiency and transparency, POMDOCTOR's model encompasses internet hospital operations and pharmaceutical supply chains. This allows for better connectivity between users, pharmacies, suppliers, and medical professionals, ultimately enhancing the patient experience and ensuring effective treatment pathways.

The company is driven by a mission to alleviate patient suffering through innovative prevention and treatment options. Their vision is to be recognized as the most trustworthy healthcare services platform available.

Financial Structure of the Offering

Under the terms of the offering, each ADS corresponds to one-sixth of a Class A ordinary share of POMDOCTOR, with a nominal value of $0.0001 per share. The registration statement for this offering was filed with the U.S. Securities and Exchange Commission (SEC) and received final approval on September 30, 2025. Investors can access the final prospectus for further details, which outlines the structure, terms, and prospects of the offering.

Regulatory Compliance and Investor Relations

As required by law, this announcement clarifies that it does not constitute an offer to sell or the solicitation of an offer to buy the company's securities. Any offers or sales of POMDOCTOR’s securities are subject to regulatory compliance under U.S. securities laws.

For those interested in the financial dynamics and operational updates of POMDOCTOR, investor inquiries can be directed to their Investor Relations Department. The company aims to maintain open communication with stakeholders, supporting transparency and fostering investor confidence.

In conclusion, POMDOCTOR LIMITED's recent success in completing the exercise of the underwriter's over-allotment option marks a pivotal moment in its growth strategy within the digital healthcare landscape. With a strong commitment to chronic disease management, POMDOCTOR is poised for further advancements in delivering quality healthcare to patients across China.